Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Gross Profit (2021 - 2025)

Historic Gross Profit for Ascendis Pharma A (ASND) over the last 5 years, with Q3 2025 value amounting to $223.6 million.

  • Ascendis Pharma A's Gross Profit rose 33664.78% to $223.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $625.5 million, marking a year-over-year increase of 10795.44%. This contributed to the annual value of $389.6 million for FY2024, which is 4441.27% up from last year.
  • Per Ascendis Pharma A's latest filing, its Gross Profit stood at $223.6 million for Q3 2025, which was up 33664.78% from $143.3 million recorded in Q2 2025.
  • Ascendis Pharma A's 5-year Gross Profit high stood at $223.6 million for Q3 2025, and its period low was $899852.1 during Q1 2021.
  • For the 5-year period, Ascendis Pharma A's Gross Profit averaged around $57.1 million, with its median value being $31.1 million (2023).
  • As far as peak fluctuations go, Ascendis Pharma A's Gross Profit surged by 105433.83% in 2022, and later plummeted by 2960.24% in 2024.
  • Ascendis Pharma A's Gross Profit (Quarter) stood at $1.6 million in 2021, then skyrocketed by 1054.34% to $18.1 million in 2022, then soared by 601.2% to $127.2 million in 2023, then skyrocketed by 34.3% to $170.9 million in 2024, then skyrocketed by 30.88% to $223.6 million in 2025.
  • Its last three reported values are $223.6 million in Q3 2025, $143.3 million for Q2 2025, and $87.8 million during Q1 2025.